Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
Selecta Biosciences (NASDAQ: SELB) is set to host a conference call on November 3, 2022, at 8:30 a.m. ET, to discuss its financial results for Q3 2022 and provide a business update. This conference call will be accessible through telephones or via the company's website. Selecta specializes in precision immune tolerance therapies utilizing its ImmTOR® platform, aimed at enhancing the efficacy of gene and biologic therapies while addressing autoimmune diseases. The company is based in the Greater Boston area.
- Potential to enhance gene therapies through ImmTOR® platform.
- Ongoing development of proprietary and partnered therapies for autoimmune diseases.
- None.
WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that it plans to host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.
Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10157874. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
When will Selecta Biosciences announce its Q3 2022 financial results?
How can I participate in the Selecta Biosciences conference call?
What is the ImmTOR® platform used by Selecta Biosciences?
